Silvant Capital Management LLC purchased a new stake in Penumbra (NYSE:PEN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,758 shares of the company’s stock, valued at approximately $319,000.
Several other institutional investors have also made changes to their positions in PEN. Advisors Preferred LLC purchased a new position in shares of Penumbra in the 1st quarter valued at about $101,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Penumbra by 45.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,691 shares of the company’s stock valued at $159,000 after purchasing an additional 532 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in shares of Penumbra in the 4th quarter valued at about $189,000. Aperio Group LLC purchased a new position in shares of Penumbra in the 4th quarter valued at about $236,000. Finally, Xact Kapitalforvaltning AB purchased a new position in shares of Penumbra in the 4th quarter valued at about $269,000. Hedge funds and other institutional investors own 73.21% of the company’s stock.
Several equities analysts recently weighed in on PEN shares. William Blair started coverage on Penumbra in a research note on Wednesday, February 21st. They issued an “outperform” rating for the company. Wells Fargo lifted their price target on Penumbra from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Canaccord Genuity restated a “buy” rating and issued a $125.00 price target on shares of Penumbra in a research note on Thursday, April 5th. Goldman Sachs started coverage on Penumbra in a research note on Wednesday, April 4th. They issued a “buy” rating and a $145.00 price target for the company. Finally, BMO Capital Markets boosted their price objective on Penumbra from $110.00 to $115.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 28th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Penumbra presently has a consensus rating of “Buy” and a consensus price target of $152.60.
In other Penumbra news, EVP Robert D. Evans sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $121.03, for a total transaction of $1,210,300.00. Following the completion of the sale, the executive vice president now directly owns 12,225 shares in the company, valued at approximately $1,479,591.75. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Lynn Rothman sold 2,273 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $115.00, for a total value of $261,395.00. Following the sale, the executive vice president now owns 154,046 shares of the company’s stock, valued at $17,715,290. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,900 shares of company stock valued at $5,653,183. 10.70% of the stock is owned by company insiders.
NYSE:PEN opened at $158.25 on Friday. Penumbra has a 12 month low of $77.75 and a 12 month high of $159.35. The company has a market cap of $5.42 billion, a price-to-earnings ratio of 1,318.75, a PEG ratio of 47.95 and a beta of -0.01.
Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, May 8th. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.08. Penumbra had a return on equity of 1.13% and a net margin of 3.65%. The company had revenue of $102.70 million during the quarter, compared to analyst estimates of $90.98 million. During the same period in the previous year, the business earned ($0.10) EPS. Penumbra’s quarterly revenue was up 40.3% on a year-over-year basis. equities analysts anticipate that Penumbra will post 0.17 earnings per share for the current year.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra (NYSE:PEN).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.